<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05115357</url>
  </required_header>
  <id_info>
    <org_study_id>34494/2/21</org_study_id>
    <nct_id>NCT05115357</nct_id>
  </id_info>
  <brief_title>Pecto-Intercostal Fascial Block Versus Transversus Thoracic Muscle Plane Block in Cardiac Surgery</brief_title>
  <official_title>Efficacy of Ultrasound-Guided Pecto-Intercostal Fascial Block Versus Transversus Thoracic Muscle Plane Block for Postoperative Analgesia in Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effect of Ultrasound-Guided Pecto-Intercostal Fascial&#xD;
      Block versus Transversus Thoracis Muscle Plane Block on Postoperative Pain Analgesia in&#xD;
      Cardiac Surgery&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Perioperative pain management is an essential component of the enhanced recovery pathway in&#xD;
      patients undergoing cardiac surgery. The incidence of severe acute postoperative pain after&#xD;
      median sternotomy is as high as 49%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative pain score</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>After extubation, patients will be evaluated for pain using numeric rating scale (NRS) score at 0,3,6,12,24 h for pain that ranged from (0 = no pain) to (10 = the worst imaginable pain). If score is ≥ 4, rescue analgesia will be given in the form of fentanyl in a dose of 0.5µg/kg by iv route.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total opioid consumption in first 24 hours after cardiac surgery</measure>
    <time_frame>24 hours Postoperative</time_frame>
    <description>If the pain score is ≥ 4, rescue analgesia will be given in the form of fentanyl in a dose of 0.5µg/kg by iv route. The time to the first request for analgesia and the total fentanyl dose will be documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of mechanical ventilation</measure>
    <time_frame>24 hours Postoperative</time_frame>
    <description>Duration of mechanical ventilation in intensive care unit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of complications</measure>
    <time_frame>24 hours Postoperative</time_frame>
    <description>Incidence of complications within 24hrs will be recorded as hematoma, pneumothorax and toxicity from local anathesitic.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pecto-Intercostal Fascial Block</condition>
  <condition>Transversus Thoracis Muscle Plane Block</condition>
  <condition>Cardiac Surgery</condition>
  <condition>Postoperative Analgesia</condition>
  <arm_group>
    <arm_group_label>Intravenous analgesia group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive systemic intravenous analgesia only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pecto-Intercostal Fascial Block (PIFB) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive PIFB on each side with an injection of 19 mL of 0.25% bupivacaine plus 1 ml of 4 mg dexamethasone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transversus Thoracis Muscle Plane Block (TTP) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive TTP on each side with an injection of 19 mL of 0.25% bupivacaine plus 1 ml of 4 mg dexamethasone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pecto-Intercostal Fascial Block</intervention_name>
    <description>A high-frequency (7-12 Mhz) linear ultrasound transducer will be placed approximately 2 cm lateral to sternal edge in the 4th or 5th intercostal space. A 22-gauge, 50-mm needle will be inserted in-plane under ultrasound guidance. The needle will be advanced through the pectoralis major muscle, and the drug will be deposited in the pecto-intercostal fascial plane located between the pectoralis major muscle and the external intercostal muscles. The separation of the fascial plane and the spread of the drug could be observed on the ultrasound image .The procedure will be repeated on the other side of sternotomy to achieve bilateral blockade.</description>
    <arm_group_label>Pecto-Intercostal Fascial Block (PIFB) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transversus Thoracis Muscle Plane Block</intervention_name>
    <description>The ultrasound probe will be placed in the longitudinal plane 1 cm lateral to the sterna border. the T4-T5 intercostal space will be identified under US. A parasternal sagittal view of the internal intercostal muscle and the transverses thoracis muscle between the 4th and 5th rib will be visualized above the pleura. A 22-gauge, 50-mm needle will be inserted inplane until the tip of the needle is located in the transversus thoracis muscle plane between the internal intercostal and transversus thoracis muscles . After excluding intravascular and intrapleural placement, local anesthetic will be administered in 5mL aliquots with intermittent aspiration.</description>
    <arm_group_label>Transversus Thoracis Muscle Plane Block (TTP) group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  90 adult patients of both sexes aged (21-60) scheduled for cardio-pulmonary bypass&#xD;
             cardiac surgery (valve replacement) with midline sternotomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients' refusal.&#xD;
&#xD;
          -  Cognitive impairment.&#xD;
&#xD;
          -  History of drug abuse&amp; chronic analgesic use&#xD;
&#xD;
          -  History of allergy to local anesthetics.&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  Pre-existing major organ dysfunction including hepatic or renal failure, pulmonary&#xD;
             insufficiency and left ventricular ejection fraction &lt; 30%&#xD;
&#xD;
          -  Known coagulopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Abdullah N. Eloraby, MD</last_name>
    <phone>0 106 352 5976</phone>
    <phone_ext>+2</phone_ext>
    <email>eloraby@med.tanta.edu.eg</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Abdullah Nabeih Abdullah Eloraby</investigator_full_name>
    <investigator_title>Assistant lecturer of Anesthesiology and Surgical Intensive Care and Pain Medicine</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The date will be available under a reasonable request of the corresponding author</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>One year after the end of the study</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

